Showing results (441-450 of 535) with videos related to

Sort By:
Pageof 54
Leukemia|May 9, 2025
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangementsAlex Bataller, Hannah E Goulart, Ghayas C Issa, et al.
Cancer|October 4, 2016
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual diseaseGhayas C Issa, Hagop M Kantarjian, C Cameron Yin, et al.
Blood|July 13, 2023
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemiaJayastu Senapati, Samuel Urrutia, Sanam Loghavi, et al.
Cancer|June 28, 2021
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapySangeetha Venugopal, Mahran Shoukier, Marina Konopleva, et al.
American Journal of Hematology|December 23, 2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitorNicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.
Cancer|June 17, 2021
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Hagop M Kantarjian, Kiyomi Morita, et al.
Blood|July 25, 2022
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysisArmin Ghobadi, Michael Slade, Hagop Kantarjian, et al.
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Leukemia & Lymphoma|September 21, 2020
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosisMusa Yilmaz, Hagop M Kantarjian, Gokce Toruner, et al.
Blood Cancer Journal|May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AMLMusa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
Pageof 54